Advertisement

Neurological Sciences

, Volume 40, Issue 10, pp 2217–2234 | Cite as

Management of epilepsy in brain tumors

  • Marta MaschioEmail author
  • Umberto Aguglia
  • Giuliano Avanzini
  • Paola Banfi
  • Carla Buttinelli
  • Giuseppe Capovilla
  • Marina Maria Luisa Casazza
  • Gabriella Colicchio
  • Antonietta Coppola
  • Cinzia Costa
  • Filippo Dainese
  • Ornella Daniele
  • Roberto De Simone
  • Marica Eoli
  • Sara Gasparini
  • Anna Teresa Giallonardo
  • Angela La Neve
  • Andrea Maialetti
  • Oriano Mecarelli
  • Marta Melis
  • Roberto Michelucci
  • Francesco Paladin
  • Giada Pauletto
  • Marta Piccioli
  • Stefano Quadri
  • Federica Ranzato
  • Rosario Rossi
  • Andrea Salmaggi
  • Riccardo Terenzi
  • Paolo Tisei
  • Flavio Villani
  • Paolo Vitali
  • Lucina Carla Vivalda
  • Gaetano Zaccara
  • Alessia Zarabla
  • Ettore Beghi
  • On behalf of Brain Tumor-related Epilepsy study group of Italian League Against Epilepsy (LICE)
Healthcare Organization
  • 240 Downloads

Abstract

Epilepsy in brain tumors (BTE) may require medical attention for a variety of unique concerns: epileptic seizures, possible serious adverse effects of antineoplastic and antiepileptic drugs (AEDs), physical disability, and/or neurocognitive disturbances correlated to tumor site. Guidelines for the management of tumor-related epilepsies are lacking. Treatment is not standardized, and overall management might differ according to different specialists. The aim of this document was to provide directives on the procedures to be adopted for a correct diagnostic-therapeutic path of the patient with BTE, evaluating indications, risks, and benefits. A board comprising neurologists, epileptologists, neurophysiologists, neuroradiologists, neurosurgeons, neuro-oncologists, neuropsychologists, and patients’ representatives was formed. The board converted diagnostic and therapeutic problems into seventeen questions. A literature search was performed in September–October 2017, and a total of 7827 unique records were retrieved, of which 148 constituted the core literature. There is no evidence that histological type or localization of the brain tumor affects the response to an AED. The board recommended to avoid enzyme-inducing antiepileptic drugs because of their interference with antitumoral drugs and consider as first-choice newer generation drugs (among them, levetiracetam, lamotrigine, and topiramate). Valproic acid should also be considered. Both short-term and long-term prophylaxes are not recommended in primary and metastatic brain tumors. Management of seizures in patients with BTE should be multidisciplinary. The panel evidenced conflicting or lacking data regarding the role of EEG, the choice of therapeutic strategy, and timing to withdraw AEDs and recommended high-quality long-term studies to standardize BTE care.

Keywords

Epilepsy Brain tumors Antiepileptic drugs Quality of life Side effects Interaction 

Notes

Compliance with ethical standards

Conflict of interest

Dr. Marta Maschio has received support to travel to congresses from Eisai Srl, has participated in scientific advisory boards for Eisai Srl, has participated in pharmaceutical industry sponsored symposia for UCB Pharma, and has received research grants from UCB Pharma. Dr. Angela La Neve has received speaker’s or consultancy fees from Eisai Srl, Mylan, Sanofi-Aventis, and UCB Pharma. Dr. Gaetano Zaccara has received speaker’s or consultancy fees from Eisai Srl, Sanofi-Aventis, and UCB Pharma. Dr. Cinzia Costa has received speaker’s or consultancy fees from Eisai Srl, FIDIA, Mylan, and UCB. Dr. Filippo Dainese has received speaker’s or consultancy fees from Eisai and UCB Pharma. Dr. Umberto Aguglia has received research grants from Biogen. Dr. Ettore Beghi has received grants from UCB Pharma and grants from Italian Ministry of Health. Dr. Federica Ranzato has participated in hospital meetings and sponsored symposia from UCB Pharma and Eisai Srl.00. The other authors declare that they have no conflict of interest.

Supplementary material

10072_2019_4025_MOESM1_ESM.docx (24 kb)
ESM 1 Details about panel members and role. (DOCX 24 kb)
10072_2019_4025_MOESM2_ESM.docx (177 kb)
ESM 2 Literature search strategy. (DOCX 177 kb)
10072_2019_4025_MOESM3_ESM.docx (115 kb)
ESM 3 Complete list of point questions (collected in domains) and of the assigned literature (DOCX 114 kb)

References

  1. 1.
    Annegers JK (1986) Risk of recurrence after an initial unprovoked seizure. Epilepsia 27(1):43–50Google Scholar
  2. 2.
    Ansari SF, Bohnstedt BN, Perkins SM, Althouse SK, Miller JC (2014) Efficacy of postoperative seizure prophylaxis in intra-axial brain tumor resections. J Neuro-Oncol 118(1):117–122Google Scholar
  3. 3.
    Arik Y, Leijten F, Seute T, Robe PA, Snijder TJ (2014) Prognosis and therapy of tumor-related versus non-tumor-related status epilepticus: a systematic review and meta-analysis. BMC Neurol 14:52Google Scholar
  4. 4.
    Artsy E, Das R et al (2009) Discontinuation of antiepileptic drugs after surgery in low grade brain tumors. Epilepsia 50:56Google Scholar
  5. 5.
    Avanzini G, Battaglia G, Franceschetti S, Spreafico R (1983) Epilepsy as a symptom of cerebral tumors. Ital J Neurol Sci Suppl 2:57–61Google Scholar
  6. 6.
    Bähr O, Hermisson M, Rona S, Rieger J, Nussbaum S, Körtvelyessy P, Franz K, Tatagiba M, Seifert V, Weller M, Steinbach JP (2012) Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. Acta Neurochir 154(2):229–235Google Scholar
  7. 7.
    Barker C, Bishop AJ, Chang M, Beal K, Chan TA (2013) Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 86(3):504–509Google Scholar
  8. 8.
    Bedetti C, Romoli M, Maschio M, di Bonaventura C, Nardi Cesarini E, Eusebi P, Siliquini S, Dispenza S, Calabresi P, Costa C (2017) Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study. Eur J Neurol 24(10):1283–1289Google Scholar
  9. 9.
    Belcastro V, Pisani LR, Bellocchi S, Casiraghi P, Gorgone G, Mula M, Pisani F (2017) Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study. J Neurol 264(5):921–927Google Scholar
  10. 10.
    Benifla M, Rutka JT, Otsubo H, Lamberti-Pasculli M, Elliott I, Sell E, RamachandranNair R, Ochi A, Weiss SK, Snead OC III, Donner EJ (2008) Long-term seizure and social outcomes following temporal lobe surgery for intractable epilepsy during childhood. Epilepsy Res 82(2–3):133–138Google Scholar
  11. 11.
    Berg AT (2008) Risk of recurrence after a first unprovoked seizure. Epilepsia 49(Suppl.1):13–18Google Scholar
  12. 12.
    Berg AK, Buckner JC, Galanis E, Jaeckle KA, Ames MM, Reid JM (2015) Quantification of the impact of enzyme inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure. J Clin Pharmacol 55(11):1303–1312Google Scholar
  13. 13.
    Bishop AJ, Chang M, Yamada Y, Beal K, Barker CA (2012) Valproic acid use during radiation therapy for glioblastoma is associated with improved survival. Int J Radiat Oncol Biol Phys 84(3):Supplement S266Google Scholar
  14. 14.
    Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’yasova D, Kruchko C, McCarthy B, Rajaraman P, Schwartzbaum JA, Sadetzki S, Schlehofer B, Tihan T, Wiemels JL, Wrensch M, Buffler PA, Brain Tumor Epidemiology Consortium (2008) Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 113:1953–1968Google Scholar
  15. 15.
    Boshuisen K, van Schooneveld MM et al (2015) Intelligence quotient improves after antiepileptic drug withdrawal following pediatric epilepsy surgery. Ann Neurol 78(1):104–114Google Scholar
  16. 16.
    Bosma I, Vos MJ, Heimans JJ, Taphoorn MJB, Aaronson NK, Postma TJ, van der Ploeg HM, Muller M, Vandertop WP, Slotman BJ, Klein M (2007) The course of neurocognitive functioning in high-grade glioma patients. Neuro-Oncology 9(1):53–62Google Scholar
  17. 17.
    Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M (2001) Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 12(2):217–219Google Scholar
  18. 18.
    Byrne TN, Cascino TL, Posner JB (1983) Brain metastasis from melanoma. J Neuro-Oncol 1(4):313–317Google Scholar
  19. 19.
    Cardona AF, Rojas L, Wills B, Bernal L, Ruiz-Patino A, Arrieta O, Jiménez Hakim E, Hakim F, Mejía JA, Useche N, Bermúdez S, Carranza H, Vargas C, Otero J, Mayo LC, Ortíz LD, Franco S, Ortíz C, Gil-Gil M, Balaña C, Zatarain-Barron ZL (2018) Efficacy and safety of levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma. J Neuro-Oncol 136:363–371Google Scholar
  20. 20.
    Chaichana KL, Parker SL et al (2009) Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. J Neurosurg 111(2):282–292Google Scholar
  21. 21.
    Chalk JB, Ridgeway K, Brophy T, Yelland JD, Eadie MJ (1984) Phenytoin impairs the bioavailability of dexametasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry 47(10):1087–1090Google Scholar
  22. 22.
    Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, Berger MS (2008) Seizure characteristics and control following resection in 332 patients with low grade gliomas. J Neurosurg 108(2):227–235Google Scholar
  23. 23.
    Commission on Classification and Terminology of the International League against Epilepsy (1981) Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489–501Google Scholar
  24. 24.
    Das RR, Artsy E, Hurwitz S, Wen PY, Black P, Golby A, Dworetzky B, Lee JW (2012) Outcome after discontinuation of antiepileptic drugs after surgery in patients with low grade tumors and meningiomas. J Neuro-Oncol 107(3):565–570Google Scholar
  25. 25.
    de Groot M, Douw L, Sizoo EM, Bosma I, Froklage FE, Heimans JJ, Postma TJ, Klein M, Reijneveld JC (2013) Levetiracetam improves verbal memory in high-grade glioma patients. Neuro-Oncology 15(2):216–223Google Scholar
  26. 26.
    Di Bonaventura C, Albini M et al (2017) Epileptic seizures heralding a relapse in high grade gliomas. Seizure 51:157–162Google Scholar
  27. 27.
    Edlund W, Gronseth G, So Y, Franklin G (2005) Clinical practice guideline process manual. American Academy of Neurology, MinnesotaGoogle Scholar
  28. 28.
    Felix FH, Trompieri NM, de Araujo OL, da Trindade KM, Fontenele JB (2011) Potential role for valproate in the treatment of high-risk brain tumors of childhood—results from a retrospective observational cohort study. Pediatr Hematol Oncol 28(7):556–570Google Scholar
  29. 29.
    Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781Google Scholar
  30. 30.
    Fisher RS (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55(4):475–482Google Scholar
  31. 31.
    Forsgren L, Beghi E, Oun A, Sillanpaa M (2005) The epidemiology of epilepsy in Europe – a systematic review. Eur J Neurol 12:245–253Google Scholar
  32. 32.
    Forsyth PA, Weaver S, Fulton D, Brasher PMA, Sutherland G, Stewart D, Hagen NA, Barnes P, Cairncross JG, DeAngelis LM (2003) Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 30(2):106–112Google Scholar
  33. 33.
    Fröscher W et al (2014) Anticonvulsant therapy for brain tumour-related epilepsy. Fortschr Neurol Psychiatr 82(12):678–690Google Scholar
  34. 34.
    Garbossa D, Panciani PP, Angeleri R, Battaglia L, Tartara F, Ajello M, Agnoletti A, Versari P, Ducati A, Fontanella M, Spena G (2013) A retrospective two-center study of antiepileptic prophylaxis in patients with surgically treated high-grade gliomas. Neurol India 61(2):131–137Google Scholar
  35. 35.
    Gilbert MR et al (2003) Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9(8):2940–2949Google Scholar
  36. 36.
    Glantz MJ, Cole BF, Friedberg MH, Lathi E, Choy H, Furie K, Akerley W, Wahlberg L, Lekos A, Louis S (1996) A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 46(4):985–991Google Scholar
  37. 37.
    Glantz MJ, Cole BF et al (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54(10):1886–1893Google Scholar
  38. 38.
    Gokhale S, Khan SA, McDonagh DL, Agrawal A, Friedman AH (2013) Levetiracetam seizure prophylaxis in craniotomy patients at high risk for postoperative seizures. Asian J Neurosurg 8(4):169–173Google Scholar
  39. 39.
    Goldlust SA, Hsu M, Lassman AB, Panageas KS, Avila EK (2012) Seizure prophylaxis and melanoma brain metastases. J Neuro-Oncol 108(1):109–114Google Scholar
  40. 40.
    Gonen T, Grossman R, Sitt R, Nossek E, Yanaki R, Cagnano E, Korn A, Hayat D, Ram ZJ (2014) Tumor location and IDH1 mutation may predict intraoperative seizures during awake craniotomy. Neurosurg. 121(5):1133–1138Google Scholar
  41. 41.
    Grossman SA (2008) Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro-Oncology 10(2):190–198Google Scholar
  42. 42.
    Grossman SA, Hochberg F et al (1998) Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The new approaches to brain tumor therapy. Cancer Chemother Pharmacol 42(2):118–126Google Scholar
  43. 43.
    Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, van den Bergh P, van Os J, Vos P, Xu W, Wittchen HU, Jönsson B, Olesen J, CDBE2010Study Group (2011) CDBE2010 Study Group. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21(10):718–779Google Scholar
  44. 44.
    Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme. J Neurosurg 118:859–865Google Scholar
  45. 45.
    Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M (2016) Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J Clin Oncol 34:731–739Google Scholar
  46. 46.
    Hardesty DA, Sanborn MR, Parker WE, Storm PB (2011) Perioperative seizure incidence and risk factors in 223 pediatric brain tumor patients without prior seizures. J Neurosurg Pediatr 7(6):609–615Google Scholar
  47. 47.
    Innocenti F et al (2004) A phase I clinical trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther 76(5):490–502Google Scholar
  48. 48.
    Islim AI, McKeever S et al (2017) The role of prophylactic antiepileptic drugs for seizure prophylaxis in meningioma surgery: a systematic review. Br J Neurosurg 31(2):149Google Scholar
  49. 49.
    Iuchi T, Hasegawa Y, Kawasaki K, Sakaida T (2015) Epilepsy in patients with gliomas: incidence and control of seizures. J Clin Neurosci 22(1):87–91Google Scholar
  50. 50.
    Jaeckle KA, Ballman K, Furth A, Buckner JC (2009) Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 73:1207–1213Google Scholar
  51. 51.
    Jallon P (2001) Newly diagnosed unprovoked epileptic seizures: presentation at diagnosis in CAROLE study. Epilepsia 42(4):464–475Google Scholar
  52. 52.
    Jallon P (2002) Epilepsy and epileptic disorders, an epidemiological marker? Contribution of descriptive epidemiology. Epileptic Disord 4:11–13Google Scholar
  53. 53.
    Kargiotis O, Markoula S, Kyritsis AP (2011) Epilepsy in the cancer patient. Cancer Chemother Pharmacol 67:489–501Google Scholar
  54. 54.
    Kerkhof M, Dielemans JC, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, Vecht CJ (2013) Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Epilepsia 54(Suppl.9):12–17Google Scholar
  55. 55.
    Kerkhof M, Koekkoek JAF et al (2016) Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom. Neuro-Oncology 18:iv61Google Scholar
  56. 56.
    Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumors. Cochrane Database Syst 8:CD008586Google Scholar
  57. 57.
    Khan RB, Onar A (2006) Seizure recurrence and risk factors after antiepilepsy drug withdrawal in children with brain tumors. Epilepsia 47(2):375–379Google Scholar
  58. 58.
    Kim YH, Kim T, Joo J, Ho Han J, Kim YJ, Kim IA, Yun C, Kim C (2015) Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. Cancer 1:2926–2932Google Scholar
  59. 59.
    Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN, Ossenkoppele GJ, van Imhoff GW, Dekker AW, Jolles J, Slotman BJ, Struikmans H, Taphoorn MJ (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360(9343):1361–1368Google Scholar
  60. 60.
    Klein M, Engelberts NH et al (2003) Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 54(4):514–520Google Scholar
  61. 61.
    Knudsen-Baas KM, Engeland A, Gilhus NE, Storstein AM, Owe JF (2016) Does the choice of antiepileptic drug affect survival in glioblastoma patients? J Neuro-Oncol 129:461–469Google Scholar
  62. 62.
    Koekkoek J et al (2014) Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom: design of a prospective observational study. BMC Neurol 14:157Google Scholar
  63. 63.
    Koekkoek JA, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Reijneveld JC, Taphoorn MJ (2015) Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. J Neurol Neurosurg Psychiatry 86(4):366–373Google Scholar
  64. 64.
    Koekkoek JA et al (2017) The withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma. Expert Rev Neurother 17(2):193–202Google Scholar
  65. 65.
    Komotar RJ, Raper DM, Starke RM, Iorgulescu JB, Gutin PH (2011) Prophylactic antiepileptic drug therapy in patients undergoing supratentorial meningioma resection: a systematic analysis of efficacy. J Neurosurg 115(3):483–490Google Scholar
  66. 66.
    Kong X, Guan J, Yang Y, Li Y, Ma W, Wang R (2015) A meta-analysis: do prophylactic antiepileptic drugs in patients with brain tumors decrease the incidence of seizures? Clin Neurol Neurosurg 134:98–103Google Scholar
  67. 67.
    Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, Tofilon PJ, Fine HA, Camphausen K (2015) A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys 92(5):986–992Google Scholar
  68. 68.
    Krumholz A (2015) Evidence-based guideline: management of an unprovoked first seizure in adults: report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 85(17):1526–1527Google Scholar
  69. 69.
    Kuhn JG (2002) Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology 16(8 Suppl 7):33–40Google Scholar
  70. 70.
    Kuhn JG (2007) Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 13(24):7401–7406Google Scholar
  71. 71.
    Kwan P, Sander JW (2004) The natural history of epilepsy: an epidemiological view. Neurol Neurosurg Psychiatry 75:1376–1381Google Scholar
  72. 72.
    Lapointe S, Florescu M, Nguyen DK, Djeffal C, Bélanger K (2015) Prophylactic anticonvulsants for gliomas: a seven-year retrospective analysis. Neuro-Oncology Pract 2(4):192–198Google Scholar
  73. 73.
    Lee MH, Kong DS, Seol HJ, Nam DH, Lee JI (2013) Risk of seizure and its clinical implication in the patients with cerebral metastasis from lung cancer. Acta Neurochir 155(10):1833–1837Google Scholar
  74. 74.
    Lee PY, Wei YT, Liang JA, Kuo YC, Chen LC, Chu CN (2017) Controversy in anti-epileptic drug as radio-sensitizer to improve survival in high grade malignant glioma: a nationwide population-based cohort study. Int J Radiat Oncol Biol Phys 99(2):E88Google Scholar
  75. 75.
    Levy G, Lervat C et al (2016) Bicentric retrospective observational study on the use of anti-epileptic drugs in children with brain tumors. Pediatr Blood Cancer 63Google Scholar
  76. 76.
    Liang S, Zhang J, Zhang S, Fu X (2016) Epilepsy in adults with supratentorial glioblastoma: incidence and influence factors and prophylaxis in 184 patients. PLoS One 11(7):e0158206Google Scholar
  77. 77.
    Lim DA, Tarapore P, Chang E, Burt M, Chakalian L, Barbaro N, Chang S, Lamborn KR, McDermott MW (2009) Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neuro-Oncol 93:349–354Google Scholar
  78. 78.
    Lobos-Urbina D, Kittsteiner-Manubens L, Peña J (2017) Is primary prevention with antiepileptic drugs effective in brain tumors or brain metastases? Medwave 17(Suppl1):e6871Google Scholar
  79. 79.
    Lockney DT, Vaziri S, Walch F, Kubilis P, Neal D, Murad GJA, Rahman M (2017) Prophylactic antiepileptic drug use in patients with brain tumors undergoing craniotomy. World Neurosurg 98:28–33Google Scholar
  80. 80.
    Loghin ME (2007) Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a North American brain tumor consortium study. Clin Cancer Res 13(23):7133–7138Google Scholar
  81. 81.
    Lwu S, Hamilton MG, Forsyth PA, Cairncross JG, Parney IF (2010) Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience. J Neuro-Oncol 96(3):403–408Google Scholar
  82. 82.
    Maschio M, Albani F, Baruzzi A (2006) Levetiracetam therapy in patients with brain tumour and epilepsy. J Neuro-Oncol 80(1):97–100Google Scholar
  83. 83.
    Maschio M, Dinapoli L, Zarabla A, Pompili A, Carapella CM, Pace A, Giannarelli D, Occhipinti E, Jandolo B (2008) Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neuro-Oncol 86(1):61–70Google Scholar
  84. 84.
    Maschio M, Dinapoli L, Vidiri A, Pace A, Fabi A, Pompili A, Carapella MC, Jandolo B (2009) The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res 28(1):60Google Scholar
  85. 85.
    Maschio M, Dinapoli L, Gomellini S, Ferraresi V, Sperati F, Vidiri A, Muti P, Jandolo B (2010) Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. J Neuro-Oncol 98(1):109–116Google Scholar
  86. 86.
    Maschio M, Dinapoli L, Sperati F, Pace A, Fabi A, Vidiri A, Muti P (2011) Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neuro-Oncol 104:205–214Google Scholar
  87. 87.
    Maschio M, Dinapoli L, Mingoia M, Sperati F, Pace A, Pompili A, Carapella CM, Vidiri A, Muti P (2011) Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol 258:2100–2104Google Scholar
  88. 88.
    Maschio M, Dinapoli L, Sperati F, Fabi A, Pace A, Vidiri A, Muti P (2012) Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. J Neuro-Oncol 106:651–656Google Scholar
  89. 89.
    Maschio M, Dinapoli L, Sperati F, Pace A, Fabi A, Vidiri A, Pompili A, Carapella CM (2012) Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. Epileptic Disord 14:388–397Google Scholar
  90. 90.
    Maschio M, Sperati F, Dinapoli L, Vidiri A, Fabi A, Pace A, Pompili A, Carapella CM, Cantelmi T (2014) Weight of epilepsy in brain tumor patients. J Neuro-Oncol 118(2):385–393Google Scholar
  91. 91.
    Maschio M, Paladin F, on behalf of the LICE brain tumor-related epilepsy study group (2015) Taking care of patients with brain tumor-related epilepsy: results from an Italian survey. Neurol Sci 36(1):125–130Google Scholar
  92. 92.
    Maschio M, Dinapoli L, Zarabla A, Maialetti A, Giannarelli D, Fabi A, Vidiri A, Cantelmi T (2017) Zonisamide in brain tumor-related epilepsy: an observational pilot study. Clin Neuropharmacol 40:113–119Google Scholar
  93. 93.
    Maschio M, Zarabla A, Maialetti A, Fabi A, Vidiri A, Villani V, Giannarelli D (2017) Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: a prospective explorative study with a historical control group. Epilepsy Behav 73:83–89Google Scholar
  94. 94.
    Maschio M, Beghi E, Casazza MML et al (2017) Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian Epilepsy Center. PLoS One 12(7):e0180470Google Scholar
  95. 95.
    Merrel RT, Anderson SK, Meyer FB, Lachance DH (2010) Seizures in patients with glioma treated with phenytoin and levetiracetam. J Neurosurg 113:1176–1181Google Scholar
  96. 96.
    Minkin K, Klein O, Mancini J, Lena G (2008) Surgical strategies and seizure control in pediatric patients with dysembryoplastic neuroepithelial tumors: a single-institution experience. J Neurosurg Pediatr 1(3):206–210Google Scholar
  97. 97.
    Mross K, Bewermeier P, Krüger W, Stockschläder M, Zander A, Hossfeld DK (1994) Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies. J Clin Oncol 12(7):1468–1474Google Scholar
  98. 98.
    Nasr ZG, Paravattil B, Wilby KJ (2016) Levetiracetam for seizure prevention in brain tumor patients: a systematic review. J Neuro-Oncol 129:1–13Google Scholar
  99. 99.
    Newton HB, Goldlust SA, Pearl D (2006) Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neuro-Oncol 78:99–102Google Scholar
  100. 100.
    Novy J, Stupp R, Rossetti AO (2009) Pregabalin in patients with primary brain tumors and seizures: a preliminary observation. Clin Neurol Neurosurg 111(2):171–173Google Scholar
  101. 101.
    Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neuro-Oncol 72:255–260Google Scholar
  102. 102.
    Ostrom QT, Barnholtz-Sloan JS (2011) Current state of our knowledge on brain tumor epidemiology. Curr Neurol Neurosci Rep 11:329–335Google Scholar
  103. 103.
    Perry JR, Sawka C (1996) Add-on gabapentin for refractory seizures in patients with brain tumours. Can J Neurol Sci 23(2):128–131Google Scholar
  104. 104.
    Perry J, Zinman L, Chambers A, Spithoff K, Lloyd N, Laperriere N, Neuro-oncology Disease Site Group, Cancer Care Ontario’s Program in Evidence-Based Care (2006) The use of prophylactic anticonvulsants in patients with brain tumours - a systematic review. Curr Oncol 13(6):222–229Google Scholar
  105. 105.
    Perucca E (2013) Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia. 54(Suppl 9):97–104Google Scholar
  106. 106.
    Phi JH, Kim SK, Cho BK, Lee SY, Park SY, Park SJ, Lee SK, Kim KJ, Chung CK (2009) Long-term surgical outcomes of temporal lobe epilepsy associated with low-grade brain tumors. Cancer 115(24):5771–5779Google Scholar
  107. 107.
    Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, Carducci MA (2005) Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro-Oncology 7(2):177–182Google Scholar
  108. 108.
    Prados MD (2006) Phase I study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-Oncology 8(1):67–78Google Scholar
  109. 109.
    Pugliatti M, Beghi E, Forsgren L, Ekman M, Sobocki P (2007) Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 48(12):2224–2233Google Scholar
  110. 110.
    Pursche S (2008) Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol 3(3):198–203Google Scholar
  111. 111.
    Radhakrishnan A, Abraham M, Radhakrishnan VV, Sarma SP, Radhakrishnan K (2006) Medically refractory epilepsy associated with temporal lobe ganglioglioma: characteristics and postoperative outcome. Clin Neurol Neurosurg 108:648–654Google Scholar
  112. 112.
    Radhakrishnan A, Abraham M, Vilanilam G, Menon R, Menon D, Kumar H, Cherian A, Radhakrishnan N, Kesavadas C, Thomas B, Sarma SP, Thomas SV (2016) Surgery for “long-term epilepsy associated tumors (LEATs)”: seizure outcome and its predictors. Clin Neurol Neurosurg 141:98–105Google Scholar
  113. 113.
    Rahman Z, Wong CH, Dexter M, Olsson G, Wong M, Gebsky V, Nahar N, Wood A, Byth K, King M, Bleasel AB (2015) Epilepsy in patients with primary brain tumors: the impact on mood, cognition, and HRQOL. Epilepsy Behav 48:88–95Google Scholar
  114. 114.
    Redjal N, Clemens Reinshagen C, Le A, Walcott BP, McDonnell E, Dietrich J, Nahed BV (2016) Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. J Neuro-Oncol 127:505–514Google Scholar
  115. 115.
    Reeves D, DiDominick S, Finn S, Kim HJ, Shake A (2016) Methotrexate elimination when coadministered with levetiracetam. Ann Pharmacother 50(12):1016–1022Google Scholar
  116. 116.
    Riva M, Landonio G, Siena S, Defanti CA (2000) The effect of anticonvulsant drugs on blood levels of methotrexate. J Neuro-Oncol 48(3):249–250Google Scholar
  117. 117.
    Rodman JH, Murry DJ, Madden T, Santana VM (1994) Altered etoposide pharmacokinetics and time to engrafment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 12(11):2390–2397Google Scholar
  118. 118.
    Roelcke U, Wyss MT, Nowosielski M, Rudà R, Roth P, Hofer S, Galldiks N, Crippa F, Weller M, Soffietti R (2016) Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. Neuro-Oncology 18(5):744–751Google Scholar
  119. 119.
    Rosati A, Tomassini A, Pollo B, Ambrosi C, Schwarz A, Padovani A, Bonetti B (2009) Epilepsy in cerebral glioma: timing of appearance and histological correlations. J Neuro-Oncol 93(3):395–400Google Scholar
  120. 120.
    Rosati A, Buttolo L, Stefini R, Todeschini A, Cenzato M, Padovani A (2010) Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. Arch Neurol 67:343–346Google Scholar
  121. 121.
    Rossetti AO, Stupp R (2010) Epilepsy in brain tumor patients. Curr Opin Neurol 23:603–609Google Scholar
  122. 122.
    Rossetti AO, Jeckelmann S, Novy J, Roth P, Weller M, Stupp R (2014) Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neuro-Oncology 16:584–588Google Scholar
  123. 123.
    Rudà R, Pellerino A, Franchino F, Bertolotti C, Bruno F, Mo F, Migliore E, Ciccone G, Soffietti R (2018) Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. J Neuro-Oncol 136:105–114Google Scholar
  124. 124.
    Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, Felten SJ, Nikcevich DA, Wiesenfeld M, Jaeckle KA, Galanis E, North Central Cancer Treatment Group (2009) Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North American central cancer treatment group results. J Neuro-Oncol 92(2):165–175Google Scholar
  125. 125.
    Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, Wen PY, Chen CC, Carter B, Lee JW, Kesari S (2013) Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. J Neurosurg 118(6):1183–1187Google Scholar
  126. 126.
    Sayegh ET, Fakurnejad S, Oh T, Bloch O, Parsa AT (2014) Anticonvulsant prophylaxis for brain tumor surgery: determining the current best available evidence. J Neurosurg 121(5):1139–1147Google Scholar
  127. 127.
    Scheffer IE, French J, Hirsch E, Jain S, Mathern GW, Moshé SL, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM (2016) Classification of the epilepsies: new concepts for discussion and debate—special report of the ILAE Classification Task Force of the Commission for Classification and Terminology. Epilepsia Open 1(1–2):37–44Google Scholar
  128. 128.
    Sepúlveda-Sánchez JM, Conde-Moreno A, Barón M, Pardo J, Reynés G, Belenguer A (2017) Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: a multicenter, observational retrospective study. Oncol Lett 13(6):4093–4100Google Scholar
  129. 129.
    Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS (2004) Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 79(12):1489–1494Google Scholar
  130. 130.
    Skardelly M, Brendle E, Noell S, Behling F, Wuttke TV, Schittenhelm J, Bisdas S, Meisner C, Rona S, Tatagiba MS, Tabatabai G (2015) Predictors of preoperative and early postoperative seizures in patients with intra-axial primary and metastatic brain tumors: a retrospective observational single center study. Ann Neurol 78(6):917–928Google Scholar
  131. 131.
    Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelen A (2009) Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 67(4):421–426Google Scholar
  132. 132.
    Spena G, Schucht P, Seidel K, Rutten GJ, Freyschlag CF, D’Agata F, Costi E, Zappa F, Fontanella M, Fontaine D, Almairac F, Cavallo M, de Bonis P, Conesa G, Foroglou N, Gil-Robles S, Mandonnet E, Martino J, Picht T, Viegas C, Wager M, Pallud J (2017) Brain tumors in eloquent areas: a European multicenter survey of intraoperative mapping techniques, intraoperative seizures occurrence, and antiepileptic drug prophylaxis. Neurosurg Rev 40(2):287–298Google Scholar
  133. 133.
    Striano S, Striano P, Boccella P, Nocerino C, Bilo L (2002) Tiagabine in glial tumors. Epilepsy Res 49:81–85Google Scholar
  134. 134.
    Sughrue ME, Rutkowski MJ, Chang EF, Shangari G, Kane AJ, McDermott MW, Berger MS, Parsa AT (2011) Postoperative seizures following the resection of convexity meningiomas: are prophylactic anticonvulsants indicated? Clinical article. J Neurosurg 114(3):705–709Google Scholar
  135. 135.
    Tandon PN, Mahapatra AK et al (2001) Epileptic seizures in supratentorial gliomas. Neurol India 49(1):55–59Google Scholar
  136. 136.
    Tanti MJ, Marson AG, Jenkinson MD (2017) Epilepsy and adverse quality of life in surgically resected meningioma. Acta Neurol Scand 136(3):246–253Google Scholar
  137. 137.
    Tinchon A, Oberndorfer S, Marosi C, Gleiss A, Geroldinger A, Sax C, Sherif C, Moser W, Grisold W (2015) Haematological toxicity of valproic acid compared to levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. J Neurol 262(1):179–186Google Scholar
  138. 138.
    Toledo M, Sarria-Estrada S, Quintana M, Maldonado X, Martinez-Ricarte F, Rodon J, Auger C, Salas-Puig, Santamarina E, Martinez-Saez E (2015) Prognostic implications of epilepsy in glioblastomas. Clin Neurol Neurosurg 139:166–171Google Scholar
  139. 139.
    Toledo M, Molins A, Quintana M, Santamarina E, Martinez-Ricarte F, Martínez-Saez E, Salas-Puig J (2018) Outcome of cancer-related seizures in patients treated with lacosamide. Acta Neurol Scand 137(1):67–75Google Scholar
  140. 140.
    Tremont-Lukats IW, Ratilal BO et al (2008) Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 2:CD004424Google Scholar
  141. 141.
    Usery JB, Michael LM 2nd et al (2010) A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neuro-Oncol 99(2):251–260Google Scholar
  142. 142.
    van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ (2009) Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 256(9):1519–1526Google Scholar
  143. 143.
    Vecht CJ, Wilms EB (2010) Seizures in low- and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther 10:663–669Google Scholar
  144. 144.
    Vecht C, Duran-Pena A, Houillier C, Durand T, Capelle L, Huberfeld G (2017) Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations. J Neuro-Oncol 133:603–607Google Scholar
  145. 145.
    Villanueva V, Saiz-Diaz R, Toledo M, Piera A, Mauri JA, Rodriguez-Uranga JJ, López-González FJ, Gómez-Ibáñez A, Garcés M, González de la Aleja J, Rodríguez-Osorio X, Palao-Duarte S, Castillo A, Bonet M, Ruiz-Giménez J, Palau J, Arcediano A, Toledo M, Gago A (2016) NEOPLASM study: real-life use of lacosamide in patients with brain tumor-related epilepsy. Epilepsy Behav 65:25–32Google Scholar
  146. 146.
    Waagemans ML, van Nieuwenhuizen D, Dijkstra M, Wumkes M, Dirven CMF, Leenstra S, Reijneveld JC, Klein M, Stalpers LJA (2011) Long-term impact of cognitive deficits and epilepsy on quality of life in patients with low-grade meningiomas. Neurosurgery 69(1):72–79Google Scholar
  147. 147.
    Wagner GL, Wilms EB et al (2003) Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 12(8):585–586Google Scholar
  148. 148.
    Watanabe S, Kuwabara Y, Suehiro S, Yamashita, Tanaka M, Tanaka A, Ohue S, Araki H (2017) Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma. Eur J Clin Pharmacol 73:357–363Google Scholar
  149. 149.
    Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for GBL. Neurology 77:1156–1164Google Scholar
  150. 150.
    Wen PY et al (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American brain tumor consortium study. Clin Cancer Res 12(16):4899–4907Google Scholar
  151. 151.
    Werner MH, Phuphanich S, Lyman GH (1995) The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. Cancer 76:1634–1642Google Scholar
  152. 152.
    Wirsching HG, Morel C, Gmu C, Neidert MC, Baumann CR, Valavanis A, Rushing EJ, Krayenbu N, Weller M (2016) Predicting outcome of epilepsy after meningioma resection. Neuro-Oncology 18(7):1002–1010Google Scholar
  153. 153.
    Wu AS, Trinh VT, Suki D, Graham S, Forman A, Weinberg JS, McCutcheon IE, Prabhu SS, Heimberger AB, Sawaya R, Wang X, Qiao W, Hess KR, Lang FF (2013) A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg 118(4):873–883Google Scholar
  154. 154.
    Wychowski T, Wang H, Buniak L, Henry JC, Mohile N (2013) Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs. Clin Neurol Neurosurg 115(11):2365–2369Google Scholar
  155. 155.
    Yat-Ming Woo P et al (2015) Risk factors for seizures and antiepileptic drug-associated adverse effects in high-grade glioma patients: a multicenter, retrospective study in Hong Kong. Surg Pract 19(1):2–8Google Scholar
  156. 156.
    Yavas C, Zorlu F et al (2011) Prospective assessment of quality of life in adult patients treated for low grade glioma. Support Care Cancer 19(2):S337Google Scholar
  157. 157.
    Yuan Y, Yunhe M, Xiang W, Yanhui L, Yanwu Y, Shuang L, Ruofei L, Jiewen L, Qing M (2014) P450 enzyme-inducing and non-enzyme-inducing antiepileptic drugs for seizure prophylaxis after glioma resection surgery: a meta-analysis. Seizure 23:616–621Google Scholar
  158. 158.
    Yuan Y, Xiang W, Qing M, Yanhui L, Jiewen L, Yunhe M (2014) Survival analysis for valproic acid use in adult glioblastoma multiforme: a meta-analysis of individual patient data and a systematic review. Seizure 23:830–835Google Scholar
  159. 159.
    Yuan Y, Peizhi Z, Maling G, Wu L, Yunhe M, Xiang W, Qing M, Yanhui L, Ruofei L, Jiewen L (2015) The efficacy of levetiracetam for patients with supratentorial brain tumors. J Clin Neurosci 22:1227–1231Google Scholar
  160. 160.
    Zachenhofer I, Donat M, Oberndorfer S, Roessler K (2011) Perioperative levetiracetam for prevention of seizures in supratentorial brain tumor surgery. J Neuro-Oncol 101(1):101–106Google Scholar

Copyright information

© Fondazione Società Italiana di Neurologia 2019

Authors and Affiliations

  • Marta Maschio
    • 1
    Email author
  • Umberto Aguglia
    • 2
  • Giuliano Avanzini
    • 3
  • Paola Banfi
    • 4
  • Carla Buttinelli
    • 5
  • Giuseppe Capovilla
    • 6
  • Marina Maria Luisa Casazza
    • 7
  • Gabriella Colicchio
    • 8
  • Antonietta Coppola
    • 9
  • Cinzia Costa
    • 10
  • Filippo Dainese
    • 11
  • Ornella Daniele
    • 12
  • Roberto De Simone
    • 13
  • Marica Eoli
    • 14
  • Sara Gasparini
    • 2
  • Anna Teresa Giallonardo
    • 15
  • Angela La Neve
    • 16
  • Andrea Maialetti
    • 1
  • Oriano Mecarelli
    • 17
  • Marta Melis
    • 18
  • Roberto Michelucci
    • 19
  • Francesco Paladin
    • 20
  • Giada Pauletto
    • 21
  • Marta Piccioli
    • 22
  • Stefano Quadri
    • 23
  • Federica Ranzato
    • 24
  • Rosario Rossi
    • 25
  • Andrea Salmaggi
    • 26
  • Riccardo Terenzi
    • 27
  • Paolo Tisei
    • 28
  • Flavio Villani
    • 29
  • Paolo Vitali
    • 30
  • Lucina Carla Vivalda
    • 31
  • Gaetano Zaccara
    • 32
  • Alessia Zarabla
    • 1
  • Ettore Beghi
    • 33
  • On behalf of Brain Tumor-related Epilepsy study group of Italian League Against Epilepsy (LICE)
  1. 1.Center for Brain Tumor-Related Epilepsy, UOSD Neuro-OncologyI.R.C.C.S. Regina Elena National Cancer InstituteRomeItaly
  2. 2.Department of Medical and Surgical SciencesMagna Graecia University of CatanzaroCatanzaroItaly
  3. 3.Department of Neurophysiology and Experimental EpileptologyCarlo Besta Neurological InstituteMilanItaly
  4. 4.Neurology Unit, Department of Emergency, Medicine Epilepsy CenterCircolo HospitalVareseItaly
  5. 5.Department of Neuroscience, Mental Health and Sensory OrgansUniversity of Rome “La Sapienza”RomeItaly
  6. 6.Department of Mental Health, Epilepsy CenterC. Poma HospitalMantuaItaly
  7. 7.Neurophysiopatology Unit, Fondazione IRCCSIstituto Neurologico C. BestaMilanItaly
  8. 8.Institute of NeurosurgeryCatholic University of the Sacred HeartRomeItaly
  9. 9.Department of Neuroscience, Reproductive and Odontostomatological Sciences, Epilepsy CentreUniversity of Naples Federico IINaplesItaly
  10. 10.Neurological Clinic, Department of Medicine, Santa Maria della Misericordia HospitalUniversity of PerugiaPerugiaItaly
  11. 11.Epilepsy Centre, UOC NeurologySS. Giovanni e Paolo HospitalVeniceItaly
  12. 12.Epilepsy Center-U.O.C. Neurology, Policlinico Paolo Giaccone, Experimental Biomedicine and Clinical Neuroscience Department (BioNeC)University of PalermoPalermoItaly
  13. 13.Neurology and Stroke Unit, Epilepsy and Sleep Disorders CenterSt. Eugenio HospitalRomeItaly
  14. 14.Molecular Neuro-Oncology UnitIRCCS-Fondazione Istituto Neurologico Carlo BestaMilanItaly
  15. 15.Neurology Unit, Human Neurosciences DepartmentSapienza UniversityRomeItaly
  16. 16.Department of Neurological and Psychiatric Sciences, Centre for EpilepsyUniversity of BariBariItaly
  17. 17.Neurology Unit, Human Neurosciences DepartmentSapienza UniversityRomeItaly
  18. 18.Department of Medical Sciences and Public Health, Institute of NeurologyUniversity of CagliariCagliariItaly
  19. 19.Unit of Neurology, Bellaria HospitalIRCCS Istituto delle Scienze Neurologiche di BolognaBolognaItaly
  20. 20.Epilepsy Center, UOC NeurologyOspedale Santi Giovanni e PaoloVeniceItaly
  21. 21.Department of NeurosciencesSanta Maria della Misericordia University HospitalUdineItaly
  22. 22.UOC NeurologyPO San Filippo NeriRomeItaly
  23. 23.USC Neurology, Epilepsy CenterASST Papa Giovanni XXIIIBergamoItaly
  24. 24.Epilepsy Centre, Neuroscience DepartmentS. Bortolo HospitalVicenzaItaly
  25. 25.Neurology and Stroke UnitSan Francesco HospitalNuoroItaly
  26. 26.Neurological DepartmentASSTLeccoItaly
  27. 27.Epilepsy Consultation Room, Neurology UnitS. Pietro Fatebenefratelli HospitalRomeItaly
  28. 28.Neurophysiology Unit, Department of Neurology-University “La Sapienza”S. Andrea HospitalRomeItaly
  29. 29.Clinical Epileptology and Experimental Neurophysiology Unit, Fondazione IRCCSIstituto Neurologico C. BestaMilanItaly
  30. 30.Neuroradiology and Brain MRI 3T Mondino Research CenterIRCCS Mondino FoundationPaviaItaly
  31. 31.Epilepsy Consultation Room, U.O.C. NeurologyRivoli HospitalTurinItaly
  32. 32.Regional Health Agency of TuscanyFlorenceItaly
  33. 33.Department of NeurosciencesIRCCS Istituto di Ricerche Farmacologiche Mario NegriMilanItaly

Personalised recommendations